Drug Profile


Alternative Names: CX-4945

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Cylene Pharmaceuticals
  • Developer Cylene Pharmaceuticals; Senhwa Biosciences
  • Class 3-ring heterocyclic compounds; Antineoplastics; Carboxylic acids; Naphthyridines; Small molecules
  • Mechanism of Action Casein kinase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cholangiocarcinoma
  • No development reported Giant lymph node hyperplasia; Multiple myeloma; Solid tumours

Most Recent Events

  • 04 Jan 2017 Silmitasertib receives Orphan Drug status for Cholangiocarcinoma in USA
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Giant-lymph-node-hyperplasia in USA (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-myeloma in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top